Revolution Medicines' pancreatic cancer drug sparks standing ovation on biotech podcast

The latest episode of STAT’s "The Readout LOUD" podcast highlighted a recent data presentation on Revolution Medicines’ pancreatic cancer candidate, daraxonrasib. Oncologists in the audience responded with a standing ovation, underscoring the excitement generated by the early findings.

The hosts discussed why the presentation resonated with the medical community, pointing to the drug’s novel mechanism and the potential impact on a disease with limited treatment options. While no formal trial results were disclosed, the enthusiasm suggested a promising direction for the therapy.

In addition to the drug discussion, the episode examined the broader market environment, noting a sharp decline in biotech stock prices that week. The conversation also veered into a lighter topic, comparing concrete beaches to traditional sand beaches.